June 10th 2025, 1:00pm
By Aaron Gerds, MD, MS
The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.
June 9th 2025, 9:00pm
By Mary Sansone
Five years after my transplant for leukemia, I’m learning to focus on gratitude despite daily struggles, remembering that being alive is the greatest gift.
June 9th 2025, 8:00pm
By Michelle Kirschner
Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship.
June 9th 2025, 7:00pm
By Ryan Scott
Natalie Schnaitmann discusses the importance of self-advocacy and access to second opinions when symptoms are dismissed among young women with cancer.
June 9th 2025, 5:00pm
By Martha Carlson
When it comes to living with cancer, your nurses make a difference.
June 9th 2025, 4:01pm
By Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
June 9th 2025, 3:00pm
By Spencer Feldman
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.
June 9th 2025, 1:28pm
By Dr. Lorenzo Cohen
It is important to understand why it is vital that patients and survivors of cancer take steps to reduce the body’s burden both before and after treatment.
June 8th 2025, 6:00pm
Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung cancer.
June 8th 2025, 2:00pm
By Jordyn Sava
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
June 7th 2025, 6:00pm
By Alex Biese
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
June 7th 2025, 2:00pm
By Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
June 6th 2025, 9:00pm
By Roman Fabbricatore
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.
June 6th 2025, 8:00pm
By Dr. Petros Grivas
Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
June 6th 2025, 7:00pm
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.
Understanding Thymoma Cancer and Its Treatment Options: A Patient Guide
Understanding Your Diagnosis: Stage 2 Oral Cavity Cancer
Understanding Your Diagnosis of Bile Duct Cancer
Understanding Your Stage 2 Uterine (Endometrial) Cancer